The Agency for Toxic Substances and Disease Registry (ATSDR) uses substance-specific minimal risk levels (MRLs) to assist in evaluating public health risks associated with exposure to hazardous substances. By definition, "MRLs are estimates of daily human exposure to a chemical that are likely to be without an appreciable risk of adverse noncancer health effects over a specified duration of exposure. " MRLs serve as screening levels for health assessors to identify contaminants and potential health effects that may be of concern for population living near hazardous waste sites and chemical releases. MRLs for each substance are derived for acute (1-14 days), intermediate (15-364 days), and chronic (365 days and longer) exposure durations, and for the oral and inhalation routes of exposure. The MRLs are derived from data compiled from a current comprehensive literature search and are presented in ATSDR's toxicological profile for that substance. In this paper we outline ATSDR's guidance for evaluating the neurological end point as discussed in the agency's toxicological profiles. Ranking neurological effects into less serious and serious categories and applying this procedure to the derivation of health guidance values or MRLs are also described. Specific examples of ATSDR MRLs based on neurological effects are presented.
INTRODUCTION
To determine the levels of significant human exposure to a given chemical associated with health effects, the Agency for Toxic Substances and Disease Registry (ATSDR) examines and interprets available toxicological and epidemiological data. The reported health effects are categorized according to severity: the no-observed-adverse-effect level (NOAEL), the less serious lowestobserved-adverse-effect level (LOAEL), and the serious LOAEL. In its Guidance for Developing Toxicological Profiles, ATSDR defines an adverse effect as &dquo;any effect that enhances the susceptibility of an organism to the deleterious effects of other chemical, physical, microbiological, or environmental influences&dquo; (ATSDR, 1994) . A dose that evokes failure in a biological system and can lead to morbidity or mortality is referred to as a serious LOAEL. After having compiled and evaluated the current database of toxicological and epidemiological studies, ATSDR derives minimal risk levels (MRLs) for the profiled substances. An MRL is an estimate of the daily human exposure to a chemical that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are derived using the NOAEL/ uncertainty factor approach. Though there are inherent uncertainties with this method, these chemical-specific estimates are intended to serve as screening levels for health assessors to identify contaminants and potential health effects that may be of concern for populations living near hazardous waste sites and chemical releases. They are not intended to define clean-up or action levels. (ATSDR, 1996; Chou et al., 1998) . MRLs are derived based on the highest NOAEL not exceeding a LOAEL, or in the absence of a NOAEL, the lowest less serious LOAEL for the most sensitive health effect endpoint for a given route and exposure period in the database. An uncertainty factor (UF) is used to account for extrapolation from a LOAEL to a NOAEL. Additional UFs may also be used for human variability, for interspecies extrapolation when animal studies are used in the absence of adequate human data, and for extrapolation across exposure durations. In addition, a modifying factor (MF) may be used, on a case-by-case basis, to reflect concerns about the database not covered by the UFs.
Thus,
MRLs for each substance are derived from data compiled from a current worldwide literature search and are presented in ATSDR's toxicological profiles for that substance. Proposed MRLs undergo review by a Health Effects/MRL Workgroup within the Division of Toxicology, external expert peer reviewers, and an agency-wide MRL Workgroup (with participation from other federal agencies), and are submitted for public comment through the toxicological profile public comment process. Each MRL is subject to change as new information becomes available concomitant with updating the toxicological profile for the substance.
Neurological Effects' In the ATSDR guidance for the preparation of a ninth set toxicological profile (ATSDR, 1995) , neurotoxicity is defined as any adverse effect on the structure or function of the central or peripheral nervous system by a biological, chemical, or physical agent. Neurological effects may be permanent or reversible, produced by neuropharmacological or neurodegenerative properties of a neurotoxicant, or may be the result of direct or indirect actions on the nervous system.
Neurological effects can be categorized as motor, mood and personality, sensory, cognitive, neurochemical, neurophysiologic, or neuropathologic. To provide guidance to agency scientists, specific end points within these effect categories have been listed and classified as less serious or serious (Table 1 ). This listing is not intended to be inclusive of all possible neurological changes that may have been reported.
Cholinesterase Activity Inhibition
Inhibition of acetylcholinesterase results in accumulation of acetylcholine at synapses and neuromuscular junctions. Exposure to pesticides such as organophosphorus compounds may produce a broad spectrum of clinical symptoms such as headaches, weakness, dizziness, blurred vision, psychosis, respiratory difficulty, paralysis, convulsions, and coma. Kaloyanova and El Batawi ( 1991 ) have reported correlation of inhibition of erythrocyte/brain cholinesterase activity with clinical symptoms (Table 2) . Acetylcholinesterase Activity (AChEA) Inhibition versus Severity of Neurological Symptoms3 -'Adapted from Kaloyanova and El Batawi, 1991. In classifying the neurological health effect end point for inhibition of erythrocyte and/or brain acetylcholinesterase activity, ATSDR considers an exposure level that causes a 20-59% inhibition of enzyme activity a less serious LOAEI.; and an exposure level that causes 60% or greater inhibition of enzyme activity a serious LOAEL. In addition, considerations are given to associated clinical symptoms. If clinical effects observed at a particular exposure level are most consistent with a moderate or severe classification, this exposure level is classified as a serious LOAEL, even if the degree of inhibition of acetylcholinesterase activity is less than 60%. Inhibition of acetylcholinesterase activity of 60% or greater is always classified as a serious effect.
RESULTS AND DISCUSSION
As mentioned previously, MRLs are based on the most sensitive end point. End points that may be used for MRL derivation include systemic effects (respiratory effects, cardiovascular effects, gastrointestinal effects, hematological effects, musculoskeletal effects, hepatic effects, renal effects, endocrine effects, dermal effects, ocular effects, body weight effects, metabolic effects), immunological and lymphoreticular effects, neurological effects, reproductive effects, and developmental effects. As of October 1997, ATSDR has derived 273 MRLs for 134 profiled substances. The neurological effects are among the most frequently used end points for deriving MRLs. To date 70 MRLs are based on neurological effects. Pertinent information on these MRLs and the associated health effects are shown in Table 3 . Forty-four of the MRLs were based on neurological effects reported in animal studies, most of which were studies in rats (28 total rat studies). Studies in mice, dogs, rabbits, and gerbils were also used as the basis for deriving MRLs. NOAELs for neurological effects were reported in 38 of these investigations; MRL guidance values were derived from NOAELs reported for neurological effects in 31 of 44 studies in animals.
Among the neurological categories, 30 MRLs were derived from effects on motor function: 11 in humans and 19 in animals. Inhibition of acetylcholinesterase accounted for 15 MRLs: 1 in humans and 14 in animals. It should be noted that 14 MRLs based on developmental neurotoxicity were considered to be based on &dquo;developmental effects&dquo; and are therefore not included in Table 3 .
Classification of neurological effects into NOAEL, less serious LOAEL, or serious LOAEL is based on degree of severity. When a less serious LOAEL is used as the basis to derive an MRL, a default UF of 10 is generally used for extrapolation from a less serious LOAEL to a NOAEL. However, an effect level is considered to be a minimal LOAEL when only minimally toxic effects are observed that are thought to represent an early indication of toxicity. A UF of 3 is generally used to extrapolate from a minimal LOAEL to a NOAEL. Representative examples where a UF of 3 was used for use of a minimal LOAEL for neurological effects in deriving an MRL are as follows:
, , An acute inhalation MRL of 26 ppm for acetone was derived based on mild decrements on behavioral performance tests in volunteers after a 4 hr exposure to 237 ppm acetone (Dick et al., 1989 ). There were small statistically significant changes in performance from controls in two measures of the auditory tone discrimination task, i.e., increased response time to correct hits and false alarm percent rate, and on the anger hostility scale (men only) of the profile of mood states test. In deriving the MRL, a UF of 9 was applied to the LOAEL of 237 ppm, 3 for use of a minimal LOAEL and 3 for human variability.
A chronic inhalation MRL of 0.3 ppm for carbon disulfide was derived based on decreased peroneal motor nerve conduction velocity and sural nerve sensory conduction velocity in workers exposed occupationally to 7.6 ppm for 12.1 years (S.D. 6.9 years) in comparison to controls. Although the small reductions in nerve conduction velocities were still within the range of clinically normal values, the authors concluded that this decrement should be considered a minimal neurotoxic effect (Johnson et al., 1983) . In calculating the MRL, a UF of 30 (3 for use of a minimal LOAEL, and 10 for human variability) was applied to the LOAEL of 7.6 ppm.
An acute inhalation MRL of 3 ppm for toluene was derived based on decreased psychomotor performance in manual dexterity and visual perception speed in workers exposed to 100 ppm toluene for 6.5 hours in comparison to unexposed controls (Baelum et al., 1985) . In deriving the MRL, a UF of 30 (3 for use of a minimal LOAEL, and 10 for human variability) was applied to the LOAEL of 100 ppm.
Because MRLs are derived through workgroup consensus, the scientific judgment of the collective body is employed. The underlying mechanism and significance of the observed neurological effects are not always clearcut. The expertise of the workgroup members, coupled with their ability to achieve consistency in making biomedical judgments across profiled substances is crucial in deriving health-based guidance values.
